+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Spinal Cord Injury - Pipeline Review, H2 2019

  • ID: 4894140
  • Drug Pipelines
  • December 2019
  • Region: Global
  • 209 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • AbbVie Inc
  • CSL Ltd
  • Hemostemix Inc
  • Mapreg SAS
  • Novoron Bioscience Inc
  • Q Therapeutics Inc
  • MORE
Spinal Cord Injury - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Spinal Cord Injury - Pipeline Review, H2 2019, provides an overview of the Spinal Cord Injury (Central Nervous System) pipeline landscape.

Spinal cord injury (SCI) is defined as damage or trauma caused to the spinal cord. SCI can lead to loss or impaired function resulting in reduced mobility or feeling. It is usually caused by trauma, transverse myelitis, polio, spina bifida or Friedreich's ataxia. Signs and symptoms of spinal cord injury include extreme back pain or pressure in the neck, head or back, paralysis in any part of the body, numbness, tingling or loss of sensation in the hands, fingers, feet or toes, loss of bladder or bowel control, difficulty in walking and impaired breathing after injury.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Spinal Cord Injury - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Spinal Cord Injury (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Spinal Cord Injury (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Spinal Cord Injury and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 7, 10, 3, 30 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 2 and 14 molecules, respectively.

Spinal Cord Injury (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Spinal Cord Injury (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Spinal Cord Injury (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Spinal Cord Injury (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Spinal Cord Injury (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Spinal Cord Injury (Central Nervous System)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Spinal Cord Injury (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Spinal Cord Injury (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AbbVie Inc
  • CSL Ltd
  • Hemostemix Inc
  • Mapreg SAS
  • Novoron Bioscience Inc
  • Q Therapeutics Inc
  • MORE
Introduction
Spinal Cord Injury - Overview
Spinal Cord Injury - Therapeutics Development
Spinal Cord Injury - Therapeutics Assessment
Spinal Cord Injury - Companies Involved in Therapeutics Development
Spinal Cord Injury - Drug Profiles
Spinal Cord Injury - Dormant Projects
Spinal Cord Injury - Discontinued Products
Spinal Cord Injury - Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Spinal Cord Injury, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Spinal Cord Injury - Pipeline by AbbVie Inc, H2 2019
Spinal Cord Injury - Pipeline by Algiax Pharmaceuticals GmbH, H2 2019
Spinal Cord Injury - Pipeline by Aposcience AG, H2 2019
Spinal Cord Injury - Pipeline by Athersys Inc, H2 2019
Spinal Cord Injury - Pipeline by BioAxone BioSciences Inc, H2 2019
Spinal Cord Injury - Pipeline by Cellatoz Therapeutics Inc, H2 2019
Spinal Cord Injury - Pipeline by CellCure, H2 2019
Spinal Cord Injury - Pipeline by CSL Ltd, H2 2019
Spinal Cord Injury - Pipeline by CSPC Pharmaceutical Group Ltd, H2 2019
Spinal Cord Injury - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2019
Spinal Cord Injury - Pipeline by EUSOL Biotech Co Ltd, H2 2019
Spinal Cord Injury - Pipeline by Fortuna Fix Inc, H2 2019
Spinal Cord Injury - Pipeline by GABA Therapeutics Inc, H2 2019
Spinal Cord Injury - Pipeline by GNT Pharma Co Ltd, H2 2019
Spinal Cord Injury - Pipeline by Helixmith Co Ltd, H2 2019
Spinal Cord Injury - Pipeline by Hemostemix Inc, H2 2019
Spinal Cord Injury - Pipeline by Hibernaid Inc, H2 2019
Spinal Cord Injury - Pipeline by Histocell SL, H2 2019
Spinal Cord Injury - Pipeline by Hope Biosciences LLC, H2 2019
Spinal Cord Injury - Pipeline by K-Stemcell Co Ltd, H2 2019
Spinal Cord Injury - Pipeline by Kringle Pharma Inc, H2 2019
Spinal Cord Injury - Pipeline by Lineage Cell Therapeutics Inc, H2 2019
Spinal Cord Injury - Pipeline by Mapreg SAS, H2 2019
Spinal Cord Injury - Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2019
Spinal Cord Injury - Pipeline by NervGen Pharma Corp, H2 2019
Spinal Cord Injury - Pipeline by NeuExcell Therapeutics Inc, H2 2019
Spinal Cord Injury - Pipeline by Neuronax SAS, H2 2019
Spinal Cord Injury - Pipeline by Neuroplast BV, H2 2019
Spinal Cord Injury - Pipeline by New World Laboratories Inc, H2 2019
Spinal Cord Injury - Pipeline by Novago Therapeutics AG, H2 2019
Spinal Cord Injury - Pipeline by Novartis AG, H2 2019
Spinal Cord Injury - Pipeline by Novoron Bioscience Inc, H2 2019
Spinal Cord Injury - Pipeline by NuNerve Pty Ltd, H2 2019
Spinal Cord Injury - Pipeline by PharmatrophiX Inc, H2 2019
Spinal Cord Injury - Pipeline by Pharmazz Inc, H2 2019
Spinal Cord Injury - Pipeline by Pharmicell Co Ltd, H2 2019
Spinal Cord Injury - Pipeline by PixarBio Corp, H2 2019
Spinal Cord Injury - Pipeline by Q Therapeutics Inc, H2 2019
Spinal Cord Injury - Pipeline by Radikal Therapeutics Inc, H2 2019
Spinal Cord Injury - Pipeline by RDD Pharma Ltd, H2 2019
Spinal Cord Injury - Pipeline by ReNetX Bio, H2 2019
Spinal Cord Injury - Pipeline by RespireRx Pharmaceuticals Inc, H2 2019
Spinal Cord Injury - Pipeline by SanBio Inc, H2 2019
Spinal Cord Injury - Pipeline by Seneca Biopharma Inc, H2 2019
Spinal Cord Injury - Pipeline by StemCyte Inc, H2 2019

List of Figures
Number of Products under Development for Spinal Cord Injury, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Top 10 Routes of Administration, H2 2019
Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • AbbVie Inc
  • Algiax Pharmaceuticals GmbH
  • Aposcience AG
  • Athersys Inc
  • BioAxone BioSciences Inc
  • Cellatoz Therapeutics Inc
  • CellCure
  • CSL Ltd
  • CSPC Pharmaceutical Group Ltd
  • Daewoong Pharmaceutical Co Ltd
  • EUSOL Biotech Co Ltd
  • Fortuna Fix Inc
  • GABA Therapeutics Inc
  • GNT Pharma Co Ltd
  • Helixmith Co Ltd
  • Hemostemix Inc
  • Hibernaid Inc
  • Histocell SL
  • Hope Biosciences LLC
  • K-Stemcell Co Ltd
  • Kringle Pharma Inc
  • Lineage Cell Therapeutics Inc
  • Mapreg SAS
  • Mitsubishi Tanabe Pharma Corp
  • NervGen Pharma Corp
  • NeuExcell Therapeutics Inc
  • Neuronax SAS
  • Neuroplast BV
  • New World Laboratories Inc
  • Novago Therapeutics AG
  • Novartis AG
  • Novoron Bioscience Inc
  • NuNerve Pty Ltd
  • PharmatrophiX Inc
  • Pharmazz Inc
  • Pharmicell Co Ltd
  • PixarBio Corp
  • Q Therapeutics Inc
  • Radikal Therapeutics Inc
  • RDD Pharma Ltd
  • ReNetX Bio
  • RespireRx Pharmaceuticals Inc
  • SanBio Inc
  • Seneca Biopharma Inc
  • StemCyte Inc
  • Stemedica Cell Technologies Inc
  • Sumitomo Dainippon Pharma Co Ltd
  • TechnoPhage SA
  • Tumorend LLC
  • Xcelthera INC
  • ZyVersa Therapeutics Inc
Note: Product cover images may vary from those shown
Adroll
adroll